Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/32191
Tipo
Trabajos presentados en eventosDerechos de autor
Acceso abierto
Colecciones
Metadatos
Mostrar el registro completo del ítem
EVALUATION OF RESULTS OF ASSOCIATION OF THE T.CRUZI CHEMOTHERAPIC BENZNIDAZOLE WITH OTHERS DRUGS (NIFURTIMOX, CETOCONAZOLE) IN THE TREATMENT OF THE EXPERIMENTAL CHAGAS DISEASE
Afiliación
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Chagas Experimental Autoimunidade e Imunologia Celular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Chagas Experimental Autoimunidade e Imunologia Celular. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Chagas Experimental Autoimunidade e Imunologia Celular. Salvador, BA, Brasil.
Resumen en ingles
Introduction: Treatment of Chagas disease, determined by infection with
Trypanosoma cruzi has been a challenge due to the different susceptibility of the
parasite strains, characterized into different biological types or Biodemes. It has
been shown that the Benznidazole (BZ) is the drug of choice for the treatment in
humans but the results are irregular in patients of different endemic areas.
Experimental data have shown a high resistance of the strains of Biodeme type
III (T. cruzi I), and irregular results in the treatment of infections with Type II strains
(T. cruzi II). The same results were obtained in the treatment with Nifurtimox (NF),
in respect to the resistance of different strains. Other drugs in clinical use for
different diseases have been assayed experimentally as the case of the
Cetoconazole (Ceto). Probably the association of different drugs could improve
the results of treatment in humans. Combinations of drugs may shorten the period
of treatment and diminish the collateral toxic effects.
Compartir